World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
52183
World Ranking
8758
National Ranking
4517

Overview

Ira M. Jacobson is affiliated with New York University in the United States and has produced extensive research in the field of medicine, with a primary focus on hepatology. Their body of work spans 188 publications, emphasizing liver-related diseases and conditions.

Their research subfields include:

  • Hepatology
  • Epidemiology
  • Surgery
  • Infectious Diseases
  • Pulmonary and Respiratory Medicine

Key topics covered in their research are:

  • Hepatitis C virus research
  • Liver Disease Diagnosis and Treatment
  • Hepatitis B Virus Studies
  • Liver Diseases and Immunity
  • Hepatitis Viruses Studies and Epidemiology
  • Gallbladder and Bile Duct Disorders
  • Liver Disease and Transplantation

Their frequent co-authors include:

  • Robert G. Gish
  • Joseph K. Lim
  • Robert J. Wong
  • Ankita Kaushik
  • Man-Fung Yuen

Jacobson has published frequently in venues such as:

  • Journal of Hepatology
  • The American Journal of Gastroenterology
  • Journal of Viral Hepatitis
  • Gastroenterology
  • UNC Libraries

Recent publications include:

  • "Prevalence of Chronic Hepatitis B Virus Infection in the United States," 2020, The American Journal of Gastroenterology
  • "Cholangiopathy After Severe COVID-19: Clinical Features and Prognostic Implications," 2021, The American Journal of Gastroenterology
  • "Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices," 2020, Alimentary Pharmacology & Therapeutics
  • "Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study," 2023, Clinical Gastroenterology and Hepatology
  • "Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial," 2023, The Lancet. Gastroenterology & Hepatology

Best Publications

  • Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

    Ira M. Jacobson;John G. McHutchison;Geoffrey Dusheiko;Adrian M. Di Bisceglie

  • Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

    Davis Gl;Balart La;Schiff Er;Lindsay K

  • Sofosbuvir for previously untreated chronic hepatitis C infection

    Eric Lawitz;Alessandra Mangia;David Wyles;Maribel Rodriguez-Torres

  • Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

    Nezam Afdhal;Stefan Zeuzem;Paul Kwo;Mario Chojkier

  • Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

    Patrick Marcellin;Edward J Gane;Maria Buti;Nezam H Afdhal

  • Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

    Mark S. Sulkowski;David F. Gardiner;Maribel Rodriguez-Torres;K. Rajender Reddy

  • Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

    Ira M. Jacobson;Stuart C. Gordon;Kris V. Kowdley;Eric M. Yoshida

  • Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

    John G. McHutchison;Gregory T. Everson;Stuart C. Gordon;Ira M. Jacobson

  • Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

    Jordan J. Feld;Ira M. Jacobson;Christophe Hézode;Tarik Asselah

  • A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B

    Robert P. Perrillo;Eugene R. Schiff;Gary L. Davis;Henry C. Bodenheimer

  • Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

    Eric Lawitz;Mark S Sulkowski;Reem Ghalib;Maribel Rodriguez-Torres

  • Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

    Paul Y Kwo;Eric J Lawitz;Jonathan McCone;Eugene R Schiff

  • Telaprevir for previously treated chronic HCV infection.

    John G. McHutchison;Michael P. Manns;Andrew J. Muir;Norah A. Terrault

  • Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus

    Alexander J. Thompson;Andrew J. Muir;Andrew J. Muir;Mark S. Sulkowski;Dongliang Ge

  • A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update

    Emmet B. Keeffe;Douglas T. Dieterich;Steven Huy B. Han;Ira M. Jacobson

  • Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates

    Zobair Younossi;Maria Stepanova;Janus P. Ong;Ira M. Jacobson

  • Thrombocytopenia associated with chronic liver disease

    Nezam Afdhal;John McHutchison;Robert Brown;Ira Jacobson

  • A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update

    Emmet B. Keeffe;Douglas T. Dieterich;Steven–Huy B. Han;Ira M. Jacobson

  • A treatment algorithm for the management of chronic hepatitis B virus infection in the United States.

    Emmet B. Keeffe;Douglas T. Dieterich;Steve Huy B. Han;Ira M. Jacobson

  • NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome

    Stefan Zeuzem;Masashi Mizokami;Stephen Pianko;Alessandra Mangia

Frequent Co-Authors

Mark S. Sulkowski
Mark S. Sulkowski Johns Hopkins University School of Medicine
Eric Lawitz
Eric Lawitz The University of Texas at Austin
John G. McHutchison
John G. McHutchison Duke University
Stefan Zeuzem
Stefan Zeuzem Goethe University Frankfurt
Andrew H. Talal
Andrew H. Talal University at Buffalo, State University of New York
Andrew J. Muir
Andrew J. Muir Duke University
Zobair M. Younossi
Zobair M. Younossi Inova Health System
Nezam H. Afdhal
Nezam H. Afdhal Beth Israel Deaconess Medical Center
Graham R. Foster
Graham R. Foster Queen Mary University of London
David R. Nelson
David R. Nelson University of Tennessee Health Science Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternatives to traditional medical degrees can open up rewarding careers in healthcare. Many students are choosing related online degrees that offer flexibility, faster entry, and diverse job opportunities.

For those interested in patient care, consider nursing programs with high acceptance rates. These offer a more accessible entry point into the nursing profession. Additionally, some students may prefer nursing school no entrance exam options, which eliminate standardized test barriers and streamline admission.

If you’re drawn to the administrative side of medicine, online healthcare management degree programs allow you to build leadership skills for roles in clinic or hospital administration.

For a role that blends healthcare and information management, look at online medical billing and coding schools that accept fafsa. These programs are ideal for those seeking quick entry into the workforce with the support of financial aid options.

Each pathway provides a unique way to launch a healthcare career, whether you want to provide hands-on care or work behind the scenes in administration or billing.

Best Scientists Citing Ira M. Jacobson

Trending Scientists